Amerigon Incorporated 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Amerigon Incorporated for the period ended June 30, 2007. Amerigon designs and markets proprietary thermoelectric devices, primarily the ClimateControl Seat (CCS), which provides heating and cooling for automotive seats. The company sells to original equipment manufacturers (OEMs) including Ford, GM, Toyota, Nissan, and Hyundai. As of June 2007, the company had shipped approximately 3.1 million CCS units since 2000.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2007 | Six Months Ended June 30, 2007 |
|---|---|---|
| Product Revenues | $15,058,000 | $31,331,000 |
| Gross Margin | $5,155,000 (34%) | $10,369,000 (33%) |
| Operating Income | $1,792,000 | $3,710,000 |
| Net Income | $1,256,000 | $2,550,000 |
| Diluted EPS | $0.06 | $0.11 |
| Cash & Equivalents | $2,237,000 | $2,237,000 (Balance Sheet) |
| Short-term Investments | $16,162,000 | $16,162,000 (Balance Sheet) |
| Total Assets | $46,859,000 | $46,859,000 (Balance Sheet) |
| Total Liabilities | $10,121,000 | $10,121,000 (Balance Sheet) |
| Working Capital | $26,500,000 | $26,500,000 |
Cash Flow (Six Months): Net cash provided by operating activities was $6,268,000. Net cash used in investing activities was $6,696,000, driven by purchases of short-term investments and patent acquisitions. Net cash provided by financing activities was $236,000.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 21% in Q2 2007 and 37% in the first half of 2007 compared to the same periods in 2006. This was driven by new model introductions (e.g., Cadillac EXT, Land Rover Range Rover) and higher volumes on redesigned models.
- Unit Shipments: Q2 2007 shipments rose to 226,000 units from 171,000 in Q2 2006. First-half shipments increased to 466,000 units from 315,000.
- Margin Expansion: Gross margin percentage improved to 34% in Q2 2007 from 31% in Q2 2006, attributed to a favorable product mix and better coverage of fixed costs.
- Geographic Shift: Revenue from Asia increased to 36% of total revenue in Q2 2007 (from 28% in 2006), while North America's share decreased to 59% (from 72%).
- Inventory Reduction: Inventory levels decreased by 61% year-over-year due to management efforts to reduce stock and a higher percentage of goods shipped directly from contract manufacturers.
Guidance, Outlook, and Risks
Management Commentary: Management expects net research and development (R&D) expenses to increase in the remainder of 2007 due to advanced thermoelectric device (TED) development. The company recently acquired Visteon Corporation's TE-based HVAC systems technology for $1.5 million to expand market opportunities in Asia and Europe. There is a noted gap in outside funding for the subsidiary BSST until new partnerships are consummated, prompting a focus on cost reductions.
Risks and Contingencies:
- Single Product Reliance: The company relies almost exclusively on the CCS product; failure to commercialize additional products could hinder growth.
- Supply Chain: Production is outsourced to Ferrotec Corporation in China. Risks include production interruptions, logistics delays, and supplier dependency.
- Customer Concentration: Sales depend on acceptance by major OEMs, who reserve the right to cancel contracts or demand price reductions.
- Intellectual Property: The company faces risks regarding patent protection and potential litigation from competitors.
- Accumulated Deficit: Despite recent profitability, the company carries an accumulated deficit of $46.9 million from historical losses.
Investor Verification Checklist
- Revenue Sustainability: Verify the longevity of new model introductions driving the 37% revenue increase and the impact of lower average unit prices.
- BSST Funding Gap: Assess the timeline for securing new development partners for the BSST subsidiary to offset the loss of Visteon funding.
- Inventory Management: Confirm that the 61% inventory reduction is sustainable and does not signal a drop in future demand.
- Related Party Transactions: Review the $11 million in purchases from Ferrotec (a related party owning 3% of stock) and the $3.9 million accounts payable balance.
- Patent Acquisition: Evaluate the strategic value of the $1.5 million Visteon patent acquisition and its impact on future R&D costs.